Our study included patients with myeloma who had a different risk of VTE, because of the presence of individual factors, such as obesity, recent surgery, presence of comorbidities, a history of VTE or treatment with erythropoietin [37]. This evidence concerns the gene EPO and plasma cell myeloma.